Branded

Zejula is now the only, once-daily PARP inhibitor approved as monotherapy treatment for recurrent ovarian cancer beyond those with a BRCA mutation in both the recurrent maintenance and late-line treatment settings.

The FDA has approved a new antibacterial drug to treat complicated UTIs.

The FDA has approved Xcopri, a new treatment for adults with partial-onset seizures.

Arakoda, the first antimalarial product approved by the Food and Drug Administration for the prevention of malaria, is being made available at select pharmacies and wholesalers.

As part of an international collaboration, the FDA has approved AstraZeneca's new treatment option for patients with chronic lymphocytic leukemia.

Novartis’ Adakveo is the first targeted therapy to treat patients with a painful complication of sickle cell disease.

Alnylam’s Givlaari has been approved by the FDA to treat a genetic disorder the causes buildup of toxic porphyrin molecules, which are formed during the production of heme.

Upsher-Smith has added Zembrace SymTouch injection to its savings program for patients